Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma

NCT ID NCT07098364

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it improves the immune system's ability to kill cancer cells. The goal is to find the best dose and measure how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma indolent B-cell non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED RECURRENT GRADE 3B FOLLICULAR LYMPHOMA RECURRENT HIGH GRADE B-CELL LYMPHOMA RECURRENT INDOLENT B-CELL NON-HODGKIN LYMPHOMA RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA REFRACTORY HIGH GRADE B-CELL LYMPHOMA REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••